An appeals court rules against the Pharmaceutical Research and Manufacturers of America in a 340B contract pharmacy dispute; for-profit investors’ acquisition of nursing homes has raised concerns about the quality of care provided in these facilities; President Joe Biden’s proposed budget for 2025 includes changes that would do away with the current system of biosimilar interchangeability.
Arkansas can prevent drug manufacturers from limiting the use of 340B drug discounts at certain pharmacies, according to a decision from the 8th US Circuit Court of Appeals, Axios reported. The Pharmaceutical Research and Manufacturers of America (PhRMA), a group that represents the largest drug makers in the US, had challenged an Arkansas law that penalized manufacturers for refusing to sell drugs to contract pharmacies, which provide discounted drugs to hospitals, clinics, and other safety-net facilities under 340B. The decision, which rested on the federal 340B law not specifying how drugs must be delivered by pharmacies to patients, may pave the way for similar laws in other states.
As more and more for-profit companies, including private equity investors, purchase nonprofit nursing homes, advocates and families are raising concerns about what this change in ownership could mean for the quality of care at these facilities, according to KFF Health News. Tactics by some investors to squeeze profit out of the nursing homes include contracting with a related company for fee-based services or collecting high rent on the facility’s real estate via a sale to a sister company, but these expenses equal fewer dollars to spend on staffing and care. Defenders of the for-profit corporations say all nursing homes are in a precarious situation due to labor shortages and low Medicaid reimbursement, and without for-profit entities stepping in, the facilities would be forced to close altogether.
President Joe Biden’s requested budget for 2025 is lower than this year’s but includes a number of priorities aligning with his health care agenda on items such as drug costs and access, biosimilars, cancer research, and more, according to Stat. Coming in at $130.7 billion vs 2024’s $144.3 billion, the proposal includes funding for a yet-to-be-created office coordinating the government’s response to drug shortages, as well as funding for the Office of Climate Change and Health Equity, which was established in 2021. The budget also proposes allowing pharmacists to fill prescriptions for reference biologics with biosimilars without needing prescriber approval, effectively discarding the interchangeability designation system.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More